NCT05904691 - Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

DRUG

OCU-10-C-110 for Injection

OCU-10-C-110 for Injection in one of 3 doses

Trial Locations (3)

RECRUITING

Raj K. Maturi, M.D., P.C., Carmel

RECRUITING

Strategic Clinical Research Group LLC, Willow Park

RECRUITING

Retina Research Institute of Texas, Abilene